Pluslife completes Series B financing to advance near-POC molecular diagnostics

Pluslife has recently completed its Series B round of financing. The round was led by FC Inovation Venture Fund and Guoju Venture Capital, with participation from Puhua Capital and Qiming Venture Partners. With the support of this new investment, Pluslife will strengthen global market expansion and scaled supply, enhance platform capabilities and industrialization, and improve the robustness and resilience of its solutions across key application areas.

Driving Access Through Technology Innovation

Pluslife is an innovation-driven in vitro diagnostics company dedicated to closing diagnostic gaps with near-POC molecular testing, enabling practical molecular testing that can be performed anytime and anywhere. Built on its proprietary isothermal amplification technology, RHAM (RNase Hybridization-Assisted Amplification), Pluslife delivers molecular diagnostics that offer PCR-comparable sensitivity in a single-tube reaction while maintaining simplified workflows suitable for decentralized settings.

Based on RHAM, Pluslife has developed the MiniDock near-POC molecular diagnostic platform and a broad portfolio of test cards that cover tuberculosis (TB), sexually transmitted infections (STIs), human papillomavirus (HPV), respiratory infections, and veterinary diagnostics. The MiniDock platform has already been deployed in multiple countries and integrated into public health projects where portable, field-ready molecular testing is required.

Global Partnerships and Implementation

Pluslife's global expansion is supported by a project grant from the Gates Foundation, focusing on innovation in TB and STI diagnostics, multi-country clinical validation, and manufacturing scale-up. The company also works closely with the World Health Organization (WHO), the Global Fund, and FIND (Foundation for Innovative New Diagnostics) on initiatives that promote standardized and accessible near-POC solutions for major infectious diseases.

In July 2025, the Pluslife MiniDock MTB Test, a TB molecular diagnostic solution built on the MiniDock platform, was listed by the Expert Review Panel for Diagnostics (ERPD), a mechanism that assesses diagnostic products for time-limited procurement through Global Fund-supported programmes. In October of the same year, Pluslife signed a long-term agreement with i+solutions, enabling access to the Stop TB Partnership's Global Drug Facility (GDF) procurement channel and further expanding compliant pathways for near-POC deployment in high-burden countries.

Industrial Upgrading and Global Layout

On the industrial side, Pluslife has established an integrated manufacturing system that spans core enzyme materials, critical reagents, and finished diagnostic products. Building on this foundation, the company is investing in a new generation of intelligent production lines to steadily expand capacity and support large-scale, multi-country implementation.

From technology innovation to global validation, and from central laboratories to front-line care, Pluslife is reshaping how molecular diagnostics are delivered. Guided by its commitment to Closing Diagnostic Gaps with Near-POC Molecular Testing, the company aims to leverage Chinese innovation and manufacturing to improve access to essential diagnostics and contribute to stronger public health systems worldwide.